Use of prednisolone in disfunction of nephron
Reading File
Finding Sources
Finding Sources
Searching PubMed
prednisolone nephrotic syndrome glomerular disease
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive data to write a thorough answer. Let me compile the full response.
Prednisolone in Nephron Dysfunction (Kidney Disease)
Prednisolone (a corticosteroid) is one of the most widely used immunosuppressants in kidney disease. It primarily targets immune-mediated glomerular injury - the podocytes, basement membrane, and mesangium that make up the filtration unit of the nephron.
Mechanism of Action in Nephron Dysfunction
Prednisolone suppresses glomerular inflammation by:
- Inhibiting T-cell activation and cytokine release (IL-2, IL-4, IL-13) that damage podocytes
- Reducing permeability of the glomerular filtration barrier, thereby decreasing proteinuria
- Suppressing mesangial cell proliferation and immune complex deposition
- Stabilizing lysosomal membranes and reducing capillary permeability
Disease-Specific Uses
1. Minimal Change Disease (MCD) - Primary Indication
MCD is the most steroid-responsive glomerular disease. Approximately 95% of children and a significant proportion of adults achieve complete remission with corticosteroids.
KDIGO 2021 Recommended Regimen (Children):
- Induction: Oral prednisolone or prednisone 60 mg/m²/day or 2 mg/kg/day (maximum 60 mg/day) as a single morning dose for 4 to 6 weeks
- Maintenance/Taper: 40 mg/m² or 1.5 mg/kg on alternate days for a further 4 to 6 weeks
- Total duration: 2 to 3 months (longer courses beyond this do not reduce relapse risk per Cochrane review)
Adults with MCD:
- Oral prednisolone 1 mg/kg/day (max 80 mg/day) or alternate-day 2 mg/kg (max 120 mg)
- Continued until complete remission for at least 4 weeks, then tapered over 6 months
- Tacrolimus monotherapy is a valid alternative for patients with contraindications to steroids (e.g., diabetes, psychosis)
(Comprehensive Clinical Nephrology, 7th Edition)
2. Focal Segmental Glomerulosclerosis (FSGS)
Prednisolone is used for primary/nephrotic forms of FSGS, though response is less predictable than in MCD:
- 20-25% of children and <50% of adults achieve complete remission
- Daily or alternate-day regimens are used; response may take 1 to 3 months (up to 8-16 weeks)
- Steroid resistance (no substantial improvement after 8-16 weeks) is defined as SRNS
- In glucocorticoid-resistant FSGS: calcineurin inhibitors (cyclosporine, tacrolimus) are used instead
- In refractory FSGS: mycophenolate mofetil (MMF) ± high-dose dexamethasone
(National Kidney Foundation Primer on Kidney Diseases, 8e)
3. Nephrotic Syndrome Relapse Patterns and Steroid Management
| Category | Definition | Management |
|---|---|---|
| Steroid-Sensitive NS (SSNS) | Complete remission after 4 weeks of prednisolone | Full course of steroids |
| Infrequent Relapsing (IRNS) | ≤1 relapse per 6 months | Repeat prednisolone course |
| Frequent Relapsing (FRNS) | ≥2 relapses per 6 months or ≥4/year | Steroid-sparing agents |
| Steroid-Dependent (SDNS) | Relapses during tapering or within 15 days of stopping | Low-dose alternate-day steroids; add cyclophosphamide, MMF, CNI, or rituximab |
| Steroid-Resistant (SRNS) | No remission after 4 weeks at full dose (children); 16 weeks (adults) | Calcineurin inhibitors, MMF |
Relapse Treatment Regimen:
- Prednisolone 60 mg/m² or 2 mg/kg/day (max 60 mg) until urine protein is negative for 3 consecutive days
- Then 40 mg/m² or 1.5 mg/kg on alternate days for 4 weeks (The Harriet Lane Handbook, 23rd Edition; Comprehensive Clinical Nephrology, 7th Edition)
4. IgA Nephropathy & Membranous Nephropathy
Prednisolone is used as part of combination regimens in these conditions, typically when proteinuria is in the nephrotic range or there is progressive GFR decline.
Altered Pharmacokinetics in Nephrotic Syndrome
An important clinical consideration: nephrotic syndrome itself alters prednisolone kinetics. Massive proteinuria reduces serum albumin, which binds prednisolone. This increases the free (active) fraction of the drug but also accelerates clearance. Hyperthyroidism and nephrotic syndrome both increase prednisolone clearance, while aging and liver disease impair it.
(Brenner and Rector's The Kidney; Rheumatology, 2-Volume Set, Elsevier)
Side Effects Relevant to Renal Patients
Prolonged high-dose prednisolone causes:
- Cushingoid features, weight gain, acne
- Hyperglycemia / steroid-induced diabetes
- Osteoporosis / osteonecrosis
- Cataracts, skin thinning
- Adrenal suppression (especially with abrupt withdrawal)
- Increased infection risk (particularly important in nephrotic patients who already have IgG loss in urine)
Summary Table
| Indication | First-Line Role | Typical Dose |
|---|---|---|
| Minimal Change Disease (child) | First-line | 2 mg/kg/day x 4-6 wk, taper |
| Minimal Change Disease (adult) | First-line | 1 mg/kg/day, taper over 6 months |
| FSGS (nephrotic, primary) | First-line (with CNI as alternative) | Daily or alternate-day; 8-16 wk trial |
| Relapse of SSNS | Repeat course | 2 mg/kg until remission, then taper |
| Steroid-dependent NS | Low-dose maintenance + sparing agents | Individualized |
| Steroid-resistant NS | Not effective alone; switch agents | CNI, MMF preferred |
Prednisolone remains the cornerstone of initial therapy for immune-mediated nephron dysfunction, particularly podocytopathies like MCD. However, in steroid-resistant or steroid-dependent cases, it must be combined with or replaced by steroid-sparing immunosuppressants to minimize long-term toxicity.
Side effects of steroids
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have sufficient material from the textbooks to give a comprehensive, well-sourced answer.
Side Effects of Steroids (Corticosteroids)
Corticosteroid side effects are dose-dependent, duration-dependent, and route-dependent. They span virtually every organ system. Short courses (1-2 weeks) carry minimal systemic risk; prolonged high-dose therapy causes the full Cushingoid picture described below.
1. Endocrine / Metabolic
| Side Effect | Details |
|---|---|
| Cushing's syndrome | Moon face, buffalo hump, truncal obesity, striae, skin thinning - the classic presentation of long-term high-dose therapy |
| Hyperglycemia / Steroid-induced diabetes | Steroids increase gluconeogenesis and cause insulin resistance; can precipitate frank type 2 DM |
| HPA axis suppression | Occurs at prednisone >7.5-10 mg/day; may persist months to years after stopping. Abrupt withdrawal causes adrenal crisis |
| Steroid withdrawal syndrome | Lassitude, musculoskeletal pains, occasional fever on rapid dose reduction |
| Weight gain / increased appetite | Common even at moderate doses |
| Hyperlipidemia | Raised total cholesterol and triglycerides |
(Goodman & Gilman's Pharmacological Basis of Therapeutics)
2. Musculoskeletal
| Side Effect | Details |
|---|---|
| Osteoporosis | Most serious long-term complication; risk of vertebral and hip fractures. Steroid-induced bone loss occurs rapidly in the first 3-6 months |
| Avascular (aseptic) necrosis | Most commonly affects the femoral head (hip); particularly disabling. Patients with lupus on steroids are especially susceptible |
| Steroid myopathy | Proximal muscle weakness (difficulty climbing stairs, rising from chair); type II muscle fiber atrophy |
| Growth suppression | In children on long-term steroids |
(Goldman-Cecil Medicine; Fitzpatrick's Dermatology)
3. Cardiovascular
| Side Effect | Details |
|---|---|
| Hypertension | Due to sodium and water retention (mineralocorticoid effect) |
| Fluid retention / edema | Salt and water retention; can worsen heart failure |
| Capillary fragility | Easy bruisability |
4. Gastrointestinal
| Side Effect | Details |
|---|---|
| Peptic ulceration | Especially when combined with NSAIDs; steroids impair mucosal defenses |
| GI bleeding | Related to peptic ulceration |
| Pancreatitis | Less common but recognised |
5. Ophthalmic
| Side Effect | Details |
|---|---|
| Posterior subcapsular cataracts | Dose- and duration-related; can occur with both systemic and high-dose inhaled steroids |
| Glaucoma | Raised intraocular pressure; more common with ocular or inhaled formulations |
6. Immunological / Infectious
| Side Effect | Details |
|---|---|
| Increased infection susceptibility | Suppressed neutrophil migration and lymphocyte function; risk of bacterial, viral (reactivation of TB, varicella, HSV), fungal infections |
| Impaired wound healing | Reduced collagen synthesis and fibroblast activity |
| Reactivation of latent TB | Screening (Mantoux/IGRA) is recommended before starting long-term steroids |
7. Psychiatric / Neurological
| Side Effect | Details |
|---|---|
| Euphoria / mania | Especially at high doses (>40 mg prednisone/day); can progress to psychosis |
| Depression | Particularly on dose tapering |
| Insomnia | Common even with short courses |
| Psychosis | Rare but serious; dose-dependent |
(Barash Clinical Anesthesia, 9e; Goodman & Gilman's)
8. Dermatological
| Side Effect | Details |
|---|---|
| Skin thinning (atrophy) | Loss of dermal collagen; particularly with topical steroids |
| Striae (stretch marks) | Irreversible skin striae from dermal breakdown |
| Acne | Steroid-induced acneiform rash |
| Hirsutism | Increased facial/body hair |
| Impaired wound healing | Skin wounds heal poorly |
9. Side Effects Specific to Inhaled Corticosteroids (ICS)
Local:
- Dysphonia (hoarse voice) - due to laryngeal muscle effects
- Oropharyngeal candidiasis (thrush) - prevented by rinsing mouth after each dose
- Cough
Systemic (dose-dependent, usually at >1500-2000 µg/day):
- Adrenal suppression
- Growth suppression in children
- Bruising
- Osteoporosis, cataracts, glaucoma
- Metabolic effects (glucose, insulin, triglycerides)
- Psychiatric disturbances
(Goodman & Gilman's Pharmacological Basis of Therapeutics)
10. Summary - Dose-Duration Relationship
| Duration / Dose | Expected Side Effects |
|---|---|
| Short course (<2 weeks) | Hyperglycemia, insomnia, mood changes, fluid retention - mostly reversible |
| Moderate (weeks to months) | Above + weight gain, acne, early osteoporosis, infection risk |
| Long-term (>3 months, high dose) | Full Cushingoid syndrome, avascular necrosis, myopathy, cataracts, significant HPA suppression, diabetes, peptic ulceration, osteoporotic fractures |
Key Clinical Precautions
- Never stop abruptly after prolonged use - taper to avoid adrenal crisis
- Calcium + Vitamin D supplementation should accompany any long-term steroid course
- Bisphosphonate prophylaxis if using >7.5 mg/day prednisone for >3 months
- Blood glucose monitoring especially in at-risk patients
- TB screening (IGRA/Mantoux) before initiating long-term therapy
- Proton pump inhibitor (PPI) co-prescription when used alongside NSAIDs
- Ophthalmology review for patients on long-term therapy (cataracts, glaucoma)
This is a shared conversation. Sign in to Orris to start your own chat.